基因变异增加了接受化疗的结肠癌病人,特别是亚裔和拉美裔病人肝脏损害的风险。 A genetic variant increases liver damage risk in colorectal cancer patients on chemo, especially those of Asian and Latin American descent.

由Mayo诊所牵头的一项研究发现,PNPLA3基因中的一种基因变异增加了接受化疗的肝脏转移的结肠癌病人肝脏损伤的风险。 A Mayo Clinic-led study has found that a genetic variant in the PNPLA3 gene increases the risk of liver damage in colorectal cancer patients with liver metastases undergoing chemotherapy. 该变体在亚裔和拉美裔人中较为常见,可能会影响肝脏如何处理化疗,从而导致更大的毒性。 The variant, more common in people of Asian and Latin American descent, may affect how the liver processes chemotherapy, leading to greater toxicity. 研究人员分析了551名病人提供的数据,并查明该联系是首次证明遗传上容易发生化疗引起的肝损伤的证据。 Researchers analyzed data from 551 patients and identified the link as the first evidence of a genetic predisposition to chemo-induced liver injury. 调查结果可能导致利用血液检测和肝脏监测进行个性化治疗计划,以减少伤害,尽管还需要进一步研究,以证实临床使用。 The finding could lead to personalized treatment plans using blood tests and liver monitoring to reduce harm, though further research is needed to confirm its clinical use.